TSX VENTURE EXCHANGE: AVI
DERMYLEX(TM) AND PSORIASIS
QUEBEC CITY, Sept. 12 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) announced today that a
post-marketing study conducted on patients suffering from psoriasis shows that
the use of Dermylex(TM) may benefit patients already using topical
corticosteroids. Using Dermylex(TM) with topical corticosteroids may create a
synergistic effect and improve overall treatment efficacy results. Therefore,
Dermylex(TM) might act as an adjuvant to topical corticosteroids.
"This new data provides Advitech and its commercial partners with
important information on treatment strategies and alternatives. Adding
Dermylex(TM) to a topical corticosteroid treatment appears to reduce psoriasis
severity," stated Dr. Christina Juneau, Advitech's Vice-President of Research
and Development. "Advitech will continue to gather and monitor additional data
and results from this post-marketing study in order to develop therapeutic
strategies for Dermylex(TM) users."
These observations arise from a study by Advitech in which Dermylex(TM)
users were invited to provide their own evaluation and comment on the results
obtained with Dermylex(TM) whether taken alone or part of a concomitant
treatment for psoriasis. In the questionnaire, psoriasis severity was
quantified by means of an intensity scale.
ADVITECH RECEIVES CONFIRMATION FROM FDA THAT DERMYLEX(TM) CLAIMS MEET U.S
Advitech had submitted to the U.S. Food and Drug Administration (FDA), in
June of this year, four different structure/function claims in relation to
Dermylex(TM) and recently received confirmation by FDA's Division of Dietary
Supplement Programs that all four claims are acceptable under the agency's
regulations. These claims will be used for labeling purpose in the
commercialization of Dermylex(TM) by Advitech's partner in the U.S market.
"Regulations applicable to the U.S market are strict as they relate to
the labeling of products like Dermylex(TM). This confirmation from the FDA is
important for Advitech and its marketing partners as it will help position
Dermylex(TM) in this strategic market," added Dr. Juneau.
About Advitech Inc. www.advitech.com
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-mediated inflammatory disorders, such as psoriasis and inflammatory
About Dermylex(TM) www.dermylex.com
Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, one of them a multi-center, double-blind, placebo-controlled trial
with 84 patients for 112 days, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available
in Canada and will soon be available in the U.S. (as BioDerm), and in France
and Belgium (as Psopax).
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
email@example.com, www.advitech.com; Serge Comeau, Investor's relations, (514)